Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Medpace Holdings Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 4.6× Medpace Holdings Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Medpace Holdings Inc for 14 Days on average.
| MDLZ | MEDP | |
|---|---|---|
Market Cap | $77.43B | $16.82B |
Volume | 7,695,104 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $630.19 |
52-Week Low | $51.51 | $393.42 |
Typical Hold Time | 107 Days | 14 Days |
Enterprise Value | $97.78B | $16.44B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.73 exceeding expectations. Revenue growth continues, reaching $38.54B in 2025, while maintaining solid profitability with 8.86% net margin. Recent dividend increase to $0.52 per share and positive news coverage highlight management's confidence in sustained performance.
MDLZ presents a compelling investment case with 76% analyst buy ratings and $70.29 consensus target, offering 16% upside. The company's global brand strength and emerging market momentum support growth, though cocoa cost pressures and competitive snack market pose risks. Cash flow stability and shareholder returns through dividends provide defensive characteristics in uncertain markets.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
